Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 23;11(1):13193.
doi: 10.1038/s41598-021-92647-5.

A microfluidic device enabling drug resistance analysis of leukemia cells via coupled dielectrophoretic detection and impedimetric counting

Affiliations

A microfluidic device enabling drug resistance analysis of leukemia cells via coupled dielectrophoretic detection and impedimetric counting

Yağmur Demircan Yalçın et al. Sci Rep. .

Abstract

We report the development of a lab-on-a-chip system, that facilitates coupled dielectrophoretic detection (DEP-D) and impedimetric counting (IM-C), for investigating drug resistance in K562 and CCRF-CEM leukemia cells without (immuno) labeling. Two IM-C units were placed upstream and downstream of the DEP-D unit for enumeration, respectively, before and after the cells were treated in DEP-D unit, where the difference in cell count gave the total number of trapped cells based on their DEP characteristics. Conductivity of the running buffer was matched the conductivity of cytoplasm of wild type K562 and CCRF-CEM cells. Results showed that DEP responses of drug resistant and wild type K562 cells were statistically discriminative (at p = 0.05 level) at 200 mS/m buffer conductivity and at 8.6 MHz working frequency of DEP-D unit. For CCRF-CEM cells, conductivity and frequency values were 160 mS/m and 6.2 MHz, respectively. Our approach enabled discrimination of resistant cells in a group by setting up a threshold provided by the conductivity of running buffer. Subsequent selection of drug resistant cells can be applied to investigate variations in gene expressions and occurrence of mutations related to drug resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Overall schematic (a) and working principle (b) of the LOC system, comprising DEP-D and IM-C units.
Figure 2
Figure 2
Fabricated LOC system emphasizing electrodes in DEP-D and IM-C units and flow distributor.
Figure 3
Figure 3
Single shell cell modeling to obtain Re(fCM) characteristics of cells having cytoplasmic conductivities of 210, 215, referring K562/wt cells, and 374 mS/m, referring K562/imaR cells, in LCB (conductivity, σ = 2.5 mS/m) (a) and relatively HCB (σ = 200 mS/m) (b). (c) Selection of the working frequency (8.6 MHz) for K562/wt and imaR cells in relatively HCB (σ = 200 mS/m). (d) Selection of the working frequency (6.2 MHz) for CCRF-CEM/wt and doxR cells in buffers (at different conductivity values: 110, 125, and 160 mS/m).
Figure 4
Figure 4
Dielectrophoretic behavior of leukemia cells and their drug resistant progenies. (a) The trapping ratio of K562/wt and K562/imaR cells immersed in relatively HCB (σ = 200mS/m) at 8.6 MHz under 20Vpp and at a flow rate of 1 µL/min. (b) The trapping ratio of CCRF-CEM/wt and CCRF-CEM/doxR cells in different buffers, with 110, 125, and 160 mS/m conductivity, at 6.2 MHz under 20Vpp and at a flow rate of 1 µL/min. Results are presented as mean ± stdev. * indicates significantly different results at the p = 0.05 level (n = 3).

References

    1. Bar-Zeev M, Livney YD, Assaraf YG. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance. Drug Resist. Update. 2017;31:15–30. doi: 10.1016/j.drup.2017.05.002. - DOI - PubMed
    1. Cui Q, et al. Modulating ROS to overcome multidrug resistance in cancer. Drug Resist. Update. 2018;41:1–25. doi: 10.1016/j.drup.2018.11.001. - DOI - PubMed
    1. Baguley BC. Multi-drug resistance in cancer. In: Zhou J, editor. Multi-Drug Resistance in Cancer. Humana Press; 2010. pp. 1–14.
    1. Cao X, Hou J, An Q, Assaraf YG, Wang X. Towards the overcoming of anticancer drug resistance mediated by p53 mutations. Drug Resist. Update. 2020;49:100671. doi: 10.1016/j.drup.2019.100671. - DOI - PubMed
    1. Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int. J. Mol. Sci. 2020;21:3233. doi: 10.3390/ijms21093233. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources